Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib + Trametinib in Advanced ALK-Positive NSCLC
NCT03087448Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Sep 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceritinib and trametinib in non-small cell lung cancer (NSCLC), sponsored by University of California, San Francisco. Primary endpoint: Maximum Tolerated Dose at 12 weeks. Started Sep 2017; status: terminated.
02
Drugs
ceritinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03087448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087448.